Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 0.96 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.72 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.72 |
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.64 |
| ▸ | HTR3A known ✓ | P46098 | 6/20 | 0.64 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.56 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.56 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.56 |
| ▸ | HTR5A known ✓ | P47898 | 2/20 | 0.56 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.56 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.56 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.56 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.56 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.56 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.56 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.56 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6577765 | 1.00 | ADRB1 (0.96) | ADRB1DRD2DRD3HTR1AHTR3A | |
| Hydrochloric Acid SCHEMBL29777392 | 1.00 | ADRB1 (0.96) | ADRB1DRD2DRD3HTR1AHTR3A | |
| Hydrochloric Acid SCHEMBL2265022 | 0.98 | ADRB1 (0.92) | ADRB1DRD2DRD3HTR1AHTR3A | |
| SCHEMBL29446047 | 0.98 | ADRB1 (1.00) | ADRB1DRD2DRD3HTR1AHTR3A | |
| SCHEMBL5785574 | 0.98 | ADRB1 (1.00) | ADRB1DRD2DRD3HTR1AHTR3A | |
| SCHEMBL230424 | 0.98 | ADRB1 (1.00) | ADRB1DRD2DRD3HTR1AHTR3A | |
| Water SCHEMBL27802433 | 0.96 | ADRB1 (0.96) | ADRB1DRD2DRD3HTR1AHTR3A | |
| Piperazine SCHEMBL28142154 | 0.96 | ADRB1 (0.96) | ADRB1DRD2DRD3HTR1AHTR3A | |
| Bromide SCHEMBL27666738 | 0.96 | ADRB1 (0.96) | ADRB1DRD2DRD3HTR1AHTR3A | |
| SCHEMBL3612685 | 0.90 | ADRB1 (0.85) | ADRB1DRD2DRD3HTR1AHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115477616-A | Preparation method of urapidil impurity | 河北广祥制药有限公司 | 2022-12-16 | — | — | CN | claimed |
| CN-110850012-B | Detection method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride and related substances thereof | 四川弘远药业有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2000056321-A1 | TREATMENT OF HYPERACTIVITY DISORDERS | KNOLL PHARMACEUTICAL COMPANY (US) | 2000-09-28 | — | — | WO | claimed |
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHUJING BIOPHARMA CO., LTD (CN) | 2024-11-07 | — | — | US | disclosed |
| EP-4382521-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shujing Biopharma Co., Ltd (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2023011608-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海枢境生物科技有限公司 | 2023-02-09 | — | — | WO | disclosed |
| CN-115477616-A | Preparation method of urapidil impurity | 河北广祥制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115477616-A | Preparation method of urapidil impurity | 河北广祥制药有限公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-110850012-B | Detection method of 1- (2, 3-dichlorophenyl) piperazine hydrochloride and related substances thereof | 四川弘远药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-107793362-B | Synthesis and application of phenyl pyridazinone derivative | 江苏恩华药业股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-0594883-A1 | Imidazo(1,2-c) quinazoline derivatives as antihypertensives and anti dysurics | NATIONAL SCIENCE COUNCIL (TW) | 1994-05-04 | — | — | EP | disclosed |
| CN-1079738-A | Heterobicyclic compounds | RECORDATI CHEM PHARM (CH) | 1993-12-22 | — | — | CN | disclosed |
| WO-1993017007-A1 | HETEROBICYCLIC COMPOUNDS | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. (IT) | 1993-09-02 | — | — | WO | disclosed |
| EP-0558245-A1 | Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1993-09-01 | — | — | EP | disclosed |
| US-5219856-A | Angiotensin-II antagonists | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0539180-A1 | Antiviral agents | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 1993-04-28 | — | — | EP | disclosed |
| US-4707550-A | N-(substituted thienyl)-N'-(substituted piperazinyl)-ureas | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-17 | — | — | US | disclosed |
| EP-0244176-A2 | Thienopyrimidine-2,4-dione derivatives and intermediates thereof | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-04 | — | — | EP | disclosed |
| US-4670560-A | VASODILATING AGENTS, HYPOTENSIVE AGENTS AND/OR CARDIOVASCULAR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368115-A1 | REGULATOR CONTAINING TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TPH1, TPH2, GAP43 | ADRB1 10/4885DRD2 327/4885DRD3 801/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | ADRB1 2811/4885DRD2 4179/4885DRD3 4518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.